Table 1.

Base-Case Drug Costs and Clinical Signals for Drugs of Interest

Annual Drug Costs
Drug	Administration	Undiscounted Annual Drug Cost,a $		Discounted Annual Drug Cost,b $
Sarilumab	SC	39,000		31,200
Adalimumab	SC	57,736		40,415
cDMARD (methotrexate)	Oral	1,155		1,155 (generic)
Clinical Signals
Drug	ACR < 20%	ACR 20-50%	ACR 50-70%	ACR 70-100%	TSS Median Difference
Sarilumab	28	25	20	27	-2.09
Adalimumab	43	25	16	16	-2.30
cDMARD (methotrexate)	73	16	8	4	0.00

^aThe annual drug cost only includes the cost of drug therapy based on the February 2017 wholesale acquisition cost and does not include any costs associated with administration or monitoring. The annual drug costs reported in this table were an average over 3 years of treatment, assuming 100% compliance to reduce the variation of some TIMs loading dosing schedule.

^bThe average discount from the wholesale acquisition cost was calculated for each drug class by comparing the 4-quarter rolling averages of net prices and wholesale acquisition cost per unit.

ACR = American College of Rheumatology improvement criteria; cDMARD = conventional disease-modifying antirheumatic drug; SC = subcutaneous; TIM = targeted immune modulator; TSS = Total Sharp Score.